Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The Justa & Lars Honors Bob Brinker Investment Club -- Ignore unavailable to you. Want to Upgrade?

To: marc ultra who wrote (12132)	2/25/2000 9:03:00 PM
From: Kirk ©	Respond to of 15132

Marc, I don't know if you have time to read my site, but I have been posting graphs that show that a LARGE, no VERY LARGE, segment of the total market HAS been in a bear market for some time. No small point. It was our friend Ralph Acampora that pointed it out to me (something he said on TV brought it to my attention). Look at Dell, PFE, IBM, T, BAC, etc...Way off their highs. 25% of the stock or some such number hit new 1 and 2 yrs lows recently! It is Totally amazing to me! yet it is what we have, a weird market. Your ENMD is a prime example. I am up 10% in some fairly conservative parts of my portfolio and it is a big winner or two dragging up the losers. OFTEN the market sees the top 5% of an investment risk pyramid impacting the overall performance. It seems that 1994 and 2000 are that way for me. Maybe you are right... the lofty stocks will crash down, but we said that about Yahoo! and AOL yrs ago and they just turned out to run from outside the Wilshire5000 right into the S&P500. Gotta admit, it is darned interesting! Glad you are on the money making side of it also. Amazes me how many fall into the "day trader trap" that they show on TV now... Forums like this are so much better! Kirk

To: marc ultra who wrote (12132)	2/26/2000 2:26:00 PM
From: marc ultra	Read Replies (3) \| Respond to of 15132

OT:Cancer and ENMD article. The Chicago Tribune will have a 3 day series on new cancer treatments starting on Sunday. On Tuesday the focus is suppose to be on a patient who is receiving Endostatin. Don't know what will be said but the reporter is one who has been closely following and one who has given favorable treatment to angiogenesis inhibitor therapy in the past. Might be a stock moving event as Endostatin trial results to date has been under a shroud of secrecy. As usual this is not a recommendation to buy at these prices. Marc